On 9 August 2024, Celltrion announced that its Zymfentra™ (infliximab-dyyb) has been included in 26 US formularies, including for 3 major Prescription Benefit Managers (PBMs), just five months after launch. According to Celltrion, the formulary listings provide 75% of coverage across the entire US insurance market.
In October 2023, Zymfentra™ was the first subcutaneous formulation of infliximab approved by the FDA, for ulcerative colitis and Crohn’s disease. Celltrion launched ZymfentraTM in the US in March 2024.
ZymfentraTM is known as Remsima SC® in Europe. Remsima SC® has been approved in Europe since 2013.